Rapid Declarative Neocortical Declarative Learning in Aging and Memory Diseases (ANéRAVIMM)

Central Nervous System Clinical Trial

— ANéRAVIMM  

Official title:

Rapid Declarative Neocortical Declarative Learning in Aging and Memory

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04846764
• Other study ID #: 35RC20_9796_ANéRAVIMM
• Status: Recruiting
• Phase: N/A
• Start date: April 28, 2021
• Est. completion date: May 28, 2024

Study information

• Verified date: July 2023
• Source: Rennes University Hospital
• Contact: Pierre-Yves Jonin
• Phone: 02 99 28 25 76
• Email: Pierreyves.JONIN[@]chu-rennes.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Learning a person's name, new words, or simply remembering where the last conversation with a friend was held are examples of associative memory, frequently disturbed in brain pathologies, but also by aging. Although typically dependent on the hippocampus in the brain, a series of findings suggest that associative memory may persist, under certain circumstances, despite hippocampal damage. The ANéRAVIMM project aims to reveal this learning system, its cognitive and cerebral bases, and to evaluate its potential in patients with memory disorders.

Description:

Three experimental cognitive tasks will be used in the ANéRAVIMM study. The first two tasks have been selected based on the literature and previous work of CHU Rennes team. They are two experiments that have produced promising results concerning the existence of a rapid neocortical learning system in declarative memory, and have in common the use of prior knowledge to promote learning.

In the first part of the study, these two tasks will be put in competition for their resistance to the effects of age. Brain aging is characterized by its deleterious impact on hippocampal functioning, and memory aging leads to an alteration of associative memory. Therefore, this first part will allow the learning paradigm that presents the best potential in brain-damaged patients to be retained in the second part of the ANéRAVIMM study.

The third task stems from recent work by CHU Rennes team in collaboration with Dr. Besson of the University of Liege, in the context of a very recent model of memory. It aims at estimating the ability to develop a representation of visual objects in memory at the entity level, i.e. an integrated representation, unifying all the perceptual, conceptual and contextual features of perceived information. This task has been adapted for the ANéRAVIMM project in order to test the hypothesis that this mnemonic representational level of the entity in memory could support rapid neocortical associative learning in declarative memory.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 94
• Est. completion date: May 28, 2024
• Est. primary completion date: May 28, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Healthy Volunteers

• aged 18 to 40 years old and aged 60 to 80 years old

• native French speaker

• right-handed

• with a level of education greater than or equal to the Certificate of Primary Education

• free of any medical or psychiatric condition that may interfere with cognition

Neurological patients

• patients with mild neurocognitive impairment due to Alzheimer's disease

• patients with semantic dementia syndrome

• right-handed patients with a right or left unilateral surgical lesion of the anterior temporal lobe as a result of pharmaco resistant temporal epilepsy, with no seizures in the last 6 months, with a memory quotient greater than 75, and free of internal extra temporal lesions on MRI

• patients with autoimmune limbic encephalitis who have been seizure-free for one month

• 1 KA patient, suffering from the rare syndrome of developmental amnesia

Exclusion Criteria:

All participants

• MRI contraindications

• sensory deficit interfering with experimental tests

• protected major (safeguard justice, trusteeship and guardianship) and persons deprived of liberty

Healthy volunteers

• deficit score on the MoCA scale according to current calibrations

Neurologic patients

• 7-items modified Hachinski ischemic score >2

• dementia

• epileptic seizure in the month prior to inclusion for epileptic patients undergoing surgery and limbic encephalitis patients

Related Conditions & MeSH terms

• Central Nervous System
• Nervous System Diseases
• Neurological Diseases

Intervention

Other:
• Neuropsychological tests
Scales and tests to evaluate: laterality anxiety depression professional level education level pre-morbid level memory disorders Experimental procedure

Locations

Country	Name	City	State
France	CHU Rennes	Rennes

Sponsors (1)

Lead Sponsor	Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference between young and old healthy subjects in experimental associative memory scores		Up to 1 month (time to perform the second visit)
Primary	Difference between healthy subjects and patients with SSHA damage in experimental associative memory scores		Up to 1 month (time to perform the second visit)
Primary	Correlations between SSHA volumes and experimental associative memory scores in healthy subjects and patients with SSHA damage		Up to 1 month (time to perform the second visit)
Primary	Correlations between rest-related functional connectivity within the Medial Temporal Lobes and experimental associative memory scores in healthy subjects		Up to 1 month (time to perform the second visit)
Secondary	Presence of significant correlations between memory scores for entity-level mnemonic representations and experimental associative memory scores in healthy subjects		Up to 1 month (time to perform the second visit)